Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA ...

Ractigen Therapeutics has received FDA clearance for an Investigational New Drug (IND) application to begin Phase I/IIa clinical trials for RAG-1C. The drug is a first-in-class small activating RNA (saRNA) therapeutic targeting Proliferative Vitreoretinopathy (PVR), a severe eye condition with no approved pharmacological treatments.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.